RDY · Dr. Reddy's Laboratories Ltd
$13.75
+4.09% last session
End-of-day data · close of 2026-10-26
Market cap
$11B
Enterprise value
$68B
Trailing P/E
38.2
Forward P/E
0.2
Dividend yield
1.0%
Beta
0.25
Avg volume
3M
Employees
28K
Daily Change %
4.09%
5 Days Change
3.93%
10 Days Change
5.20%
30 Days Change
12.24%
60 Days Change
12.89%
Month to Day Change
12.24%
Year to Day Change
-1.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RDY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-29
Latest call per bank · past 12 months
Citigroup
Buy$1,450
+10445.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Citigroup | Upgrade | Sell → Buy | $1,040 → $1,450 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- bearish: RSI (14): RSI is 74 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 11.0% above the 50-day MA ($12.39).
- bullish: Price vs 200-day MA: Trading 4.6% above the 200-day MA ($13.14).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.08) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($11.30) and high ($15.27).
RDY Price Chart
Loading chart for RDY…
Fundamentals
About Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 31.1% YTD
TEVA
Teva Pharmaceutical Industries
$47B 28.0% YTD
HLN
Haleon plc
$45B 2.9% YTD
ZTS
Zoetis Inc.
$33B -34.6% YTD
UTHR
United Therapeutics Corporation
$25B 21.7% YTD
VTRS
Viatris Inc.
$21B 50.4% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 2.9% YTD
ELAN
Elanco Animal Health Incorporat
$11B 1.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.